全文获取类型
收费全文 | 244019篇 |
免费 | 37719篇 |
国内免费 | 2728篇 |
专业分类
耳鼻咽喉 | 6103篇 |
儿科学 | 7715篇 |
妇产科学 | 4087篇 |
基础医学 | 15287篇 |
口腔科学 | 3180篇 |
临床医学 | 36442篇 |
内科学 | 65713篇 |
皮肤病学 | 8608篇 |
神经病学 | 24242篇 |
特种医学 | 10018篇 |
外国民族医学 | 3篇 |
外科学 | 55895篇 |
综合类 | 1306篇 |
现状与发展 | 72篇 |
一般理论 | 131篇 |
预防医学 | 14906篇 |
眼科学 | 5319篇 |
药学 | 7307篇 |
中国医学 | 114篇 |
肿瘤学 | 18018篇 |
出版年
2024年 | 543篇 |
2023年 | 5145篇 |
2022年 | 2023篇 |
2021年 | 5026篇 |
2020年 | 7158篇 |
2019年 | 4136篇 |
2018年 | 9681篇 |
2017年 | 8893篇 |
2016年 | 10093篇 |
2015年 | 10399篇 |
2014年 | 18501篇 |
2013年 | 19834篇 |
2012年 | 12749篇 |
2011年 | 13144篇 |
2010年 | 14559篇 |
2009年 | 17900篇 |
2008年 | 12620篇 |
2007年 | 11223篇 |
2006年 | 13393篇 |
2005年 | 10420篇 |
2004年 | 9564篇 |
2003年 | 7888篇 |
2002年 | 7649篇 |
2001年 | 4508篇 |
2000年 | 3458篇 |
1999年 | 3986篇 |
1998年 | 4724篇 |
1997年 | 4256篇 |
1996年 | 3997篇 |
1995年 | 3791篇 |
1994年 | 2471篇 |
1993年 | 2098篇 |
1992年 | 1767篇 |
1991年 | 1751篇 |
1990年 | 1349篇 |
1989年 | 1434篇 |
1988年 | 1261篇 |
1987年 | 1115篇 |
1986年 | 1098篇 |
1985年 | 978篇 |
1984年 | 830篇 |
1983年 | 764篇 |
1982年 | 838篇 |
1981年 | 674篇 |
1980年 | 575篇 |
1979年 | 396篇 |
1978年 | 453篇 |
1977年 | 498篇 |
1975年 | 341篇 |
1972年 | 346篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Dana Franzen-Klein Mark Jankowski Charlotte L. Roy Hoa Nguyen-Phuc Da Chen Lorin Neuman-Lee 《Journal of toxicology and environmental health. Part A》2020,83(2):45-65
ABSTRACTDomestic chickens (Gallus gallus domesticus) were exposed to imidacloprid by gavage once daily for 7 consecutive days at 0, 0.03, 0.34, 3.42, 10.25, and 15.5 mg/kg/day (n = 20 per group; 5 6-week-old males, 5 6-week-old females, 5 9-week-old males, and 5 9-week-old females). The severity and duration of neurobehavioral abnormalities were recorded. Components of the innate and adaptive immune system were assessed with 7 standard functional assays. Temporary neurobehavioral abnormalities were observed in a dose-dependent manner, including muscle tremors, ataxia, and depressed mentation. Based upon mean clinical severity scores, the no observed adverse effect level (NOAEL) was 3.42 mg/kg/day, and the lowest observed adverse effect level (LOAEL) was 10.25 mg/kg/day. The effective dose value for the presence of any neurobehavioral abnormalities in 50% of the test group (ED50) was 4.62 ± 0.98 mg/kg/day. The ED50 for an adjusted score that included both severity and duration of neurobehavioral abnormalities was 11.24 ± 9.33 mg/kg/day. These ED50 values are equivalent to a 1 kg bird ingesting 29 or 70 imidacloprid treated soybean seeds respectively. Immunotoxicity was not documented, possible causes include the assays were insensitive, relevant immune functions were not examined, or imidacloprid is not immunotoxic at this dosing schedule in this species. Neurobehavioral abnormalities were a more sensitive indicator of the sublethal effects of imidacloprid than immunotoxicity. 相似文献
52.
53.
54.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
55.
56.
57.
Mark Verrill 《Surgery (Oxford)》2019,37(3):181-185
Multimodality primary therapies for breast cancer combined with earlier detection have led to a sharp decline in the death rate from breast cancer in the UK over the last 40 years in the face of a rising incidence. The latest UK statistics from Cancer Research UK report 55,122 new cases of breast cancer in 2015 with 11,563 deaths from breast cancer recorded in 2016. Crudely, this equates to a cure rate of around 80% for all comers and demonstrates a clear improvement in outcome with 50,285 new cases in 2011 and 11,716 deaths in 2012. Despite this good news, there are still significant numbers of women (and men) who suffer from either a local recurrence or metastatic disease following apparently successful treatment for early breast cancer (Stage I to III). Only a minority of individuals, 6.6% with the stage recorded at diagnosis, present with stage IV disease. This review considers the treatment options available to individuals with locally recurrent and advanced breast cancer (ABC). 相似文献
58.
59.
60.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献